NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Zevra Therapeutics, Inc. (ZVRA) Stock Analysis

Zevra Therapeutics, Inc. (ZVRA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ZVRA

$10.36

−$0.11 (−1.05%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ZVRA with… →

ZVRA Key Statistics

As of Oct 21, 2026
Trading
Open
$10.48
Previous Close
$10.47
Day's Range
10.32–10.50
52-Week Range
8.01–15.04
Volume
500.32K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.98
Valuation
Market Cap
$615.22M
P/E Ratio
10.91
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
9.62
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
10.67
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.52
EPS (ttm)Profit attributable to each share over the last twelve months.
0.95
Financials (FY)
Revenue (FY)
$106.47M+350.91%
Net Income (FY)
$83.23M
Profit marginThe share of revenue left as profit after all costs and taxes.
42.82%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
59.38M
1-Year Return
−6.67%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
1.06M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ZVRA closed at $10.36, −6.67% over 1 year.

Zevra Therapeutics, Inc. (ZVRA) has a market capitalization of $615.22M.

In fiscal 2025, ZVRA reported revenue of $106.47M.

ZVRA Stock Return by Calendar Year

Zevra Therapeutics, Inc. (ZVRA) 10-year return: what $10,000 became

1 year
$10,000 $9,333
−6.67%
5 years
$10,000 $10,637
+6.37%
10 years
$10,000 $1,750
−82.50%

If you had invested $10,000 in Zevra Therapeutics, Inc. (ZVRA) 10 years ago, at the close on October 21, 2016, it would have been worth $1,750 at the close on October 21, 2026: −82.50% in total, −16.00% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+15.62%
2025+7.43%
2024+27.33%
2023+42.70%
2022−47.30%
2021−22.23%
2020+84.70%
2019−78.71%
2018−56.05%
2017+37.29%
2016 (partial year)−28.74%

As of October 21, 2026.

ZVRA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$106.47M$83.23M78.2%
2024$23.61M−$105.51M−446.9%
2023$27.46M−$46.05M−167.7%
2022$10.16M−$26.77M−263.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$106.47M$89.99M−$4.23M$83.23M78.2%
2024$23.61M$16.20M−$87.00M−$105.51M−446.9%
2023$27.46M$25.29M−$49.60M−$46.05M−167.7%
2022$10.16M$9.94M−$24.90M−$26.77M−263.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ZVRA Valuation vs Biotechnology Median

Median of 608 stocks
MetricZVRABiotechnology medianvs median
P/E10.9116.6034% below
P/S ratio4.5213.3066% below
Profit margin42.82%−38.31%81.1 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 18 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Zevra Therapeutics, Inc. (ZVRA) at $615.22M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 61.

The most recent close on file for ZVRA is $10.36, dated October 21, 2026. That is −$0.11 (−1.05%) against the previous close. Over the past 52 weeks the price has ranged from $8.01 to $15.04. The latest close sits 29.34% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $106.47M. That is +350.91% against the prior fiscal year, when revenue was $23.61M. Net income for the same year was $83.23M. Profit margin runs at 42.82%. That is 81.1 percentage points above the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to 0.95.

Across the 4 fiscal years on file, revenue moves from $10.16M in 2022 to $106.47M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 10.91. That is 34.28% below the Biotechnology median of 16.6. The forward P/E on file is 9.62. The PEG ratio, which sets the P/E against expected earnings growth, reads 10.67. The price-to-sales ratio is 4.52. On price-to-sales that is 66% below the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.98. Daily returns over the trailing 10 years annualize to a volatility of 82.53%. The trailing one-year total return is −6.67%. Across 10 years the annualized return works out at −16.00%.

Growth & Income

The record shows no dividend for ZVRA.

Across the complete calendar years on file, 2020 returned +84.70% and 2019 returned −78.71%. Of the 9 complete calendar years on file, 5 finished higher. So far in 2026 the total return is +15.62%.

Peer Comparison

Zevra Therapeutics, Inc. (ZVRA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Zevra Therapeutics, Inc. ZVRA $615.22M 10.9
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Zevra Therapeutics, Inc. trades at a P/E of 10.9.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Visit website →